{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:00:10Z","timestamp":1780394410612,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":4385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1093\/annonc\/mdm405","type":"journal-article","created":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T22:40:18Z","timestamp":1193352018000},"page":"1995-1999","source":"Crossref","is-referenced-by-count":59,"title":["Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis"],"prefix":"10.1016","volume":"18","author":[{"given":"D.J.","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Capanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Raggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kemeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm405_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics 2004","volume":"54","author":"Jewel","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdm405_bb0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","article-title":"Liver resection for colorectal metastases","volume":"15","author":"Fong","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"Folfiri followed by Folfox 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0025","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm405_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colon cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm405_bb0035","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdm405_bb0040","first-page":"10","article-title":"Management of liver metastases from colorectal cancer","volume":"20","author":"Kemeny","year":"2006","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm405_bb0045","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion vs systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0050","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.1994.12.11.2288","article-title":"Phase II study of hepatic arterial floxuridine, leucovorin and dexamethoasone for unresectable liver metastases from colorectal cancer","volume":"12","author":"Kemeny","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.20286","article-title":"Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma","volume":"91","author":"Kemeny","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0060","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1200\/JCO.2001.19.10.2687","article-title":"Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer","volume":"19","author":"Kemeny","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0065","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2005.07.100","article-title":"Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer","volume":"23","author":"Kemeny","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0070","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2307\/2529881","article-title":"Maximally selected rank statistics","volume":"38","author":"Miller","year":"1982","journal-title":"Biometrics"},{"issue":"6","key":"10.1093\/annonc\/mdm405_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1586\/14737140.6.6.921","article-title":"First- and second-line therapy of metastatic colorectal cancer","volume":"6","author":"Terstriep","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdm405_bb0080","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/jco.2005.23.16_suppl.3508","article-title":"Randomized phase II study of cetuximab\/bevacizumab\/irinotecan (CBI) versus cetuximab\/bevacizumab (CB) in irinotecan refractory colorectal cancer","volume":"23","author":"Saltz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm405_bb0085","first-page":"16S","article-title":"An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer","volume":"23","author":"Fields","year":"2005","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419404158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419404158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/12\/1995\/562695\/mdm405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:58:00Z","timestamp":1624438680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419404158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0923753419404158"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm405","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}